

LYPLA3 Antibody (C-term) Blocking peptide

Synthetic peptide Catalog # BP11706b

Specification

LYPLA3 Antibody (C-term) Blocking peptide - Product Information

Primary Accession

Q8NCC3

LYPLA3 Antibody (C-term) Blocking peptide - Additional Information

Gene ID 23659

Other Names

Group XV phospholipase A2, 231-, 1-O-acylceramide synthase, ACS, LCAT-like lysophospholipase, LLPL, Lysophospholipase 3, Lysosomal phospholipase A2, LPLA2, PLA2G15, LYPLA3

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

LYPLA3 Antibody (C-term) Blocking peptide - Protein Information

Name PLA2G15 (HGNC:17163)

Synonyms LYPLA3

Function

Has dual calcium-independent phospholipase and O- acyltransferase activities with a potential role in glycerophospholipid homeostasis and remodeling of acyl groups of lipophilic alcohols present in acidic cellular compartments (PubMed:10092508, PubMed:11790796, PubMed:20410020, PubMed:23958596, PubMed:239724779, PubMed:25727495, PubMed:10092508, PubMed:10092508, PubMed:10092508, PubMed:10092508, PubMed:20410020, PubMed:20410020, PubMed:203958596,



PubMed:29724779, PubMed: 25727495). Among preferred fatty acyl donors are phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols and phosphatidylserines (PubMed:29724779). Favors sn-2 over sn-1 deacylation of unsaturated fatty acyl groups of phosphatidylcholines and phosphatidylethanolamines (By similarity). Among preferred fatty acyl acceptors are natural lipophilic alcohols including short-chain ceramide N-acetyl-sphingosine (C2 ceramide), alkylacylglycerols, monoacylglycerols, and acylethanolamides such as anandamide and oleoylethanolamide (PubMed:29724779). Selectively hydrolyzes the sn-1 fatty acyl group of truncated oxidized phospholipids and may play a role in detoxification of reactive oxidized phospholipids during oxidative stress (PubMed:30830753). Required for normal phospholipid degradation in alveolar macrophages with potential implications in pulmonary surfactant clearance (By similarity). At neutral pH, hydrolyzes the sn-1 fatty acyl group of the lysophosphatidylcholines (PubMed: 10092508).

Cellular Location

Lysosome. Secreted. Membrane; Peripheral membrane protein

Tissue Location

Detected in blood plasma (at protein level) (PubMed:10092508, PubMed:20410020). Ubiquitous. Highly expressed in heart, placenta, skeletal muscle, kidney and pancreas. Detected at lower levels in spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocytes (PubMed:10092508)

LYPLA3 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides

LYPLA3 Antibody (C-term) Blocking peptide - Images

LYPLA3 Antibody (C-term) Blocking peptide - Background

The protein encoded by this gene is a member of theprotein tyrosine phosphatase (PTP) family. PTPs are known to besignaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, andoncogenic transformation. This PTP contains an extracellulardomain, a single transmembrane segment and two tandemintracytoplasmic catalytic domains, and thus belongs to receptortype PTP. This gene is specifically expressed in hematopoieticcells. This PTP has been shown to be an essential regulator of T-and B-cell antigen receptor signaling. It functions through eitherdirect interaction with components of the antigen receptorcomplexes, or by activating various Src family kinases required forthe antigen receptor signaling. This PTP also suppresses JAKkinases, and thus functions as a regulator of cytokine receptorsignaling. Four alternatively spliced transcripts variants of thisgene, which encode distinct isoforms, have been reported. [providedby RefSeq].

LYPLA3 Antibody (C-term) Blocking peptide - References

Heyd, F., et al. Mol. Cell 40(1):126-137(2010)Wu, Z., et al. J. Immunol. 185(1):231-238(2010)Cui, J., et al. Arthritis Rheum. 62(7):1849-1861(2010)Booth, N.J., et al. J. Immunol. 184(8):4317-4326(2010)Capitanescu, B., et al. Rom | Morphol Embryol 51(1):49-54(2010)